In short
Clinical trials are studying Vorinostat in people with advanced or recurrent squamous cell cancers of the head and neck, cervix, anus, vulva/vagina, and penis. These studies mainly look at whether Vorinostat, often with other treatment, can help control cancer and improve response rates.
Key points
- Clinical trials of Vorinostat in the provided data focus on advanced squamous cell cancers, including cancers of the head and neck, cervix, anus, vulva/vagina, penis, and lung. The main study is a Phase 2 interventional trial with 112 participants. It tests Vorinostat together with pembrolizumab, not as a stand-alone treatment. The main goal is to measure overall response rate, which shows how many patients have their tumors shrink. The trial includes patients with recurrent and/or metastatic disease, and the lung group was closed to recruitment.
Trial overview
The provided trial data describe one interventional study, which means researchers gave treatment and then measured the results. This study was a Phase 2 trial and it was completed. The trial enrolled 112 people.
The study tested Vorinostat together with pembrolizumab in patients with advanced mucosal squamous cell cancers. The brief summary says the trial looked at the antitumor activity of this combination in recurrent and/or metastatic disease.
Who was studied
The trial included patients with squamous cell carcinoma of the head and neck, cervix, anus, vulva/vagina, and penis. The conditions listed in the source also include squamous cell carcinoma of the lung, but the lung cohort was closed to recruitment.
These cancers are described in the study as advanced, recurrent, and/or metastatic. In simple words, this means the cancer had come back, spread, or was already far along when patients entered the study.
Treatment and study design
Vorinostat was given with pembrolizumab in this trial. The intervention list shows Vorinostat as an oral drug and pembrolizumab as an intravenous treatment.
The study title and summary both point to the same main idea: the researchers wanted to see whether this combination could help patients with difficult-to-treat mucosal cancers. Because this was a Phase 2 study, the main purpose was to look for signs that the treatment might work in this patient group.
What was measured
The main endpoint was overall response rate (ORR). ORR is the percentage of patients whose best tumor response was either a complete response or a partial response.
A complete response means no visible signs of cancer remain, while a partial response means the cancer got smaller but did not disappear completely. The trial measured response using RECIST v1.1, which is a standard method for checking changes in tumor size during a study.
What the trial aimed to show
The main goal was to evaluate the antitumor activity of pembrolizumab combined with Vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma. Antitumor activity means whether the treatment can help stop the cancer from growing or make it shrink.
The trial focused on several body sites, not just one cancer type, which shows it was designed for a group of related mucosal cancers. The source data do not provide other endpoint details beyond ORR, so the main measured outcome in this article is the tumor response rate.
Key patient points
- Vorinostat was studied in a combination treatment with pembrolizumab, not by itself.
- The trial was for people with advanced squamous cell cancers of the head and neck, cervix, anus, vulva/vagina, penis, and lung.
- The study was completed and included 112 participants.
- The main result was ORR, a simple way to measure how many patients had their tumors shrink.
- The lung cohort was closed to recruitment, so that group was no longer enrolling new patients.